Daniel P. Cahill, M.D.,Ph.D.
This page shows the publications co-authored by Daniel Cahill and Bruce Rosen.
Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41.
Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013 Sep; 123(9):3659-63.
Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol. 2016 11; 18(11):1569-1578.
Sherry apple resident travel scholarship 194 assessment of treatment response in isocitrate dehydrogenase-mutant gliomas by quantification of 2-hydroxyglutarate with in vivo 3-dimensional magnetic resonance spectroscopy. Neurosurgery. 2014 Aug; 61 Suppl 1:224.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.